Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Vaxcyte, Inc. (PCVX) Balance Sheet

As of 2026-06-30 (10-Q), Vaxcyte, Inc. (PCVX) reported total assets of $3.1B, total liabilities of $380.2M and shareholders' equity of $2.8B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $183.2M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PCVXVaxcyte, Inc.Follow PCVX — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
9.0B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days
LineFY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents0.390.070.830.400.390.170.18
Short-term investments—0.180.100.681.361.391.30
Current assets0.390.260.941.101.791.631.55
Total assets0.390.321.011.413.513.003.14
Current liabilities0.050.030.040.150.140.210.27
Total liabilities0.050.040.050.170.210.320.38
Shareholders' equity0.350.280.951.243.312.692.76

USD billions · SEC XBRL

Vaxcyte, Inc. — questions

How much cash does Vaxcyte, Inc. have?
$183.2M in cash and cash equivalents as of 2026-06-30.
What are Vaxcyte, Inc.'s total assets?
$3.1B as of 2026-06-30.
What is Vaxcyte, Inc.'s shareholders' equity?
$2.8B as of 2026-06-30.

Every figure on this page comes from Vaxcyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.